Boris Ziser, Schulte Roth & Zabel’s Finance Group co-head and Rebecca Berrebi, founder and CEO at Avenue 33 LLC authored a recent article in Law360, “Top 3 Litigation Finance Deal-Killers, And How To Avoid Them.”

Their piece highlights the increasing interest of private capital and other capital sources in litigation finance, especially amid market volatility. Litigation finance — where funders invest in legal claims — sits at the intersection of law and finance and carries unique complexities. Boris and Rebecca note that while potentially lucrative, these deals sometimes fall apart due to issues of trust, misunderstood terms and delays. They outline that building early transparency, ensuring mutual understanding of obligations and maintaining clear timelines are critical in avoiding deal failures. The authors emphasize that success in litigation finance relies on proactive communication, well-drafted agreements and realistic expectations.

Read the article.

“At a time when biotechs are struggling to raise funds, the convergence with Artificial Intelligence technologies is attracting new investors who are more tech-savvy and less life science-oriented.”

Partner Anthony Paronneau explains the changes taking place and the challenges facing entrepreneurs at this crossroads in an interview with Jacques-Bernard Taste.

Read the full article in French (via paywall).

Ele Klein, Schulte’s Chair of the Global Shareholder Activism Group, contributed to an article which details the escalating conflict between Harley-Davidson and activist investor H Partners Management.

Ele highlighted that while boards must manage the risks of activism, they should also recognize the benefits — especially when those directors push for accountability and performance improvements.

He noted that activist-nominated directors have access to analytics not typically available to most directors. These activists have “deep resources and a significant financial stake” and are “incentivized to maximize shareholder returns,” Ele stated.